0001209191-18-028492.txt : 20180508
0001209191-18-028492.hdr.sgml : 20180508
20180508080845
ACCESSION NUMBER: 0001209191-18-028492
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180507
FILED AS OF DATE: 20180508
DATE AS OF CHANGE: 20180508
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Holles Natalie C.
CENTRAL INDEX KEY: 0001580111
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37833
FILM NUMBER: 18813026
MAIL ADDRESS:
STREET 1: C/O HYPERION THERAPEUTICS, INC.
STREET 2: 2000 SIERRA POINT PARKWAY, SUITE 400
CITY: BRISBANE
STATE: CA
ZIP: 94005
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Audentes Therapeutics, Inc.
CENTRAL INDEX KEY: 0001628738
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 461606174
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 600 CALIFORNIA ST., 17TH FLOOR
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94108
BUSINESS PHONE: 415-638-6556
MAIL ADDRESS:
STREET 1: 600 CALIFORNIA ST., 17TH FLOOR
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94108
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-05-07
0
0001628738
Audentes Therapeutics, Inc.
BOLD
0001580111
Holles Natalie C.
C/O AUDENTES THERAPEUTICS, INC.
600 CALIFORNIA STREET, 17TH FLOOR
SAN FRANCISCO
CA
94108
0
1
0
0
President and COO
Stock Option (right to buy)
36.39
2018-05-07
4
A
0
25000
0.00
A
2028-05-07
Common Stock
25000
25000
D
The option vests as to 2.0833% of the total shares monthly, beginning June 2, 2018, with 100% of the total shares vested and exercisable on May 2, 2022, subject to the reporting person's provision of service to the issuer on each vesting date.
/s/ Thomas Soloway as attorney-in-fact for Natalie Holles
2018-05-08